IMUGENE RECEPTOR MIMIC TECHNOLOGY PATENT GRANTED IN U.S.Imugene (ASX ASX See: Australian Stock Exchange : IMU Noun 1. IMU - a terrorist group of Islamic militants formed in 1996; opposes Uzbekistan's secular regime and wants to establish an Islamic state in central Asia; is a conduit for drugs from Afghanistan to central Asian countries ), Sydney, Australia, has been granted patent protection for its Receptor Mimic Technology (RMT RMT right mentotransverse (position of the fetus). RMT 1. Registered Massage Therapist 2. Renal mesenchymal tumor ) in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. through to 2020. The RMT is the platform for existing and new Imugene products for pigs, poultry and cattle, including one of the company's lead products to prevent E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. post weaning weaning, n the period of transition from breast feeding to eating solid foods. weaning the act of separating the young from the dam that it has been sucking, or receiving a milk diet provided by the dam or from artificial sources. diarrhoea in pigs. Receptor mimic products act as an extremely efficient biological 'sponge', binding toxins or disease causing organisms and harmlessly carrying them out of the body. Unlike new or existing antibiotics or antimicrobials, there is no potential for food residues, no chance of resistance developing and the products are safe for widespread use in all mammalian species. The RMT also has many applications in human medicine and Imugene holds an equity interest in BioMimic, the company with the commercial rights to develop RMT products for the human market. Imugene Managing Director, Dr Warwick Lamb commented, "The granting of this key patent is very significant because the United States is the highest value market for our products. This patent grant covers RMT use in both animals and humans. The RMT E. coli preventative for pigs is currently undergoing clinical trials. Post weaning diarrhoea caused by E. coli is one of the most economically damaging bacterial diseases in pig production. The market for E. coli disease preventative treatments in pigs is estimated to be over US$450 million per annum Per annum Yearly. . We anticipate expanding the E. coli product for use in poultry and possibly cattle. The patent has previously been granted in Australia and New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. . About Imugene Imugene specializes in commercializing animal health products for production animals including pigs, poultry and cattle. Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues. Imugene owns the worldwide rights to two platform technologies. The Receptor Mimic Technology for gastrointestinal diseases of pigs and potentially all other animal species. Secondly, the Adenoviral Vector Delivery System for pigs and poultry delivers Imugene's highly effective poultry productivity enhancer. Imugene's poultry and pig portfolio is targeting a worldwide US$3 billion annual market and replace existing chemical and antibiotic products. Consumer demands for residue free food and health regulatory pressures will bolster Imugene's prospects. For more information, visit http://www.imugene.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion